The study is testing a new medicine called BI 764532 for adults with a specific type of advanced cancer known as neuroendocrine cancer (NEC). NEC is a type of cancer that starts in the hormone-producing cells of the body's organs. The study is for people whose tumors have a marker called DLL3. The medicine is given along with chemotherapy, which is a treatment that uses strong drugs to kill cancer cells. The study has two parts: Part A finds the highest dose of BI 764532 that can be tolerated, and Part B checks how well people tolerate the medicine with different chemotherapies.
Participants receive BI 764532 and chemotherapy through a vein. They can stay in the study for up to three years if they're doing well and handling the treatment. Regular doctor visits are needed to check health, track any side effects, and measure tumor size.
- Lasts up to 3 years if tolerated.
- Regular doctor visits required.
- Must have a specific type of advanced cancer.